Our company news

We are working on the following new projects: • We signed 2 contracts with a new sponsor for bioequivalence studies of the drugs with INN Rivaroxaban (dosages 10 and 20 mg)

Clinical Trials Day is celebrated around the world 0n 20 of May.

We are working on the following new projects: • Smooth was awarded by 4 projects in Russia for medical writing and data management and 1 in Lithuania for data management.

We are working on the following new projects: • We signed a WO for CTD modules preparation with our global Sponsor. • We signed 2 contracts for specification documents

We are happy to present our new signed projects: • Contract for CTA submission of the final report with a new Sponsor. • Agreement for a bioequivalence study (INN: Dutasteride + Tamsulosin).

New contracts were signed in December: • A contract for submission of the final report to the Ministry of Health of the Russian Federation. • Medical writing agreement with our long-term Sponsor.

New projects started in November: • Bioequivalence trial (INN: Azacitidine). • Medical writing project (INN: Amtolmetin guacil).

We were working on the following new projects in October: • We signed a contract for data management and medical writing project of clinical study in Russia.

We were working on the following new projects in September: • Observational trial is being initiated in dermatology • We signed a contract for a bioequivalence study (INN: Paracetamol) with long-term sponsor

We were working on the following new projects in August: • We are in the process of final negotiation of the contract for a BE study with a Czech company

We were working on the following new projects in July: • Our company signed a contract for a BE study (INN: Drotaverine) from a big Russian pharma • We finalized a contract for III phase study in patients with arthrosis • We won a tender performed by a leading Russian vaccine company for full services projects

The projects are moving regardless the pandemic situation:Nimesulide phase II study data base is lockedCTA was performed in our phase II study in COVID-19, SIVs are performedLast patient last visit was performed in our phase III PID study in childrenCSR in etoricoxib trial was submitted to MoHDysmenorrhoea pain phase III study is initiatedClinical part in schizophrenia phase III is close to an endClose out visit was performed in Erlotinib trial

Measures to promote patients safety during COVID-19 pandemic include: Direct to patients shipment of investigational drug

We were working on the following new projects in May: Smooth Drug Development signed several contracts for medical writing

Smooth Drug Development is happy to share its March news